Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine the effectiveness of sertraline administration after a stroke in preventing the onset of post-stroke depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antidepressant Discontinuation in Treatment Resistant Depression

NCT03786614

Treatment Resistant Depression

UNKNOWN NA

Treatment of Post-Traumatic Brain Injury (TBI) Depression

NCT00233103

Depression

COMPLETED PHASE2

Selenium as Augmentation Treatment for Sertraline Resistant Major Depression

NCT02890212

Major Depression

SUSPENDED NA

Preventing Depression Recurrence in Diabetes

NCT00374426

Major Depression Diabetes

COMPLETED PHASE4

Study of Medication and Placebo Response in Major Depression

NCT00229476

Depressive Disorder, Major

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Persons who suffer from a stroke are at high risk for developing post-stroke major depression (PSMD), an illness that has a negative impact on post-stroke physical rehabilitation and is associated with increased morbidity and mortality. Unfortunately, early detection and successful treatment of post-stroke major depression improves, but does not normalize, stroke rehabilitation outcomes compared to stroke survivors who never developed post-stroke depression. Therefore, preventing the onset of PSMD and its associated disability is an attractive possibility. This study is a placebo controlled, 10-month double-blind trial of sertraline in the prevention of PSMD in stroke survivors, with a 2-month naturalistic continuation phase. The primary outcome will be the incidence of Major Depression post-stroke. Additional outcomes will include the severity of depressive symptoms post-stroke and the level of disability experienced by the two treatment groups. An exploratory analysis will also be conducted to elucidate participant characteristics that may be moderators of the participants' response to the preventive intervention, thereby refining the profile of disabled stroke survivors most likely to benefit from the preventive intervention.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00781326

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Accident Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Sertraline

Group Type ACTIVE_COMPARATOR

sertraline

Intervention Type DRUG

Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.

2

matching placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

matching placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sertraline

Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.

Intervention Type DRUG

Placebo

matching placebo tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ischemic stroke within 3 months of study entry
* Admitted to a UPMC hospital for acute inpatient treatment or rehabilitation of stroke
* Speaks English
* Females willing to use an effective form of birth control throughout the study

Exclusion Criteria

* Meets DSM-IV-TR criteria for a major depressive episode
* History of any bipolar disorder
* Psychotic or history of a psychotic disorder
* Meets DMS-IV TR criteria for alcohol or substance abuse or dependence criteria within 3 months of study entry
* Current treatment with antidepressant medication for any reason (e.g., anxiety disorder, neuropathic pain)
* Primary hemorrhagic stroke
* Language impairment severe enough to prevent valid neuropsychiatric assessment
* History of another CNS disease other than prior stroke or psychiatric illness (e.g., head trauma, multiple sclerosis, HIV with CNS involvement)
* Pulse \<50 or \>100 beats per minute
* Significant hyponatremia (Na \<130meq)
* Current hypothyroid state
* Medically unstable including symptoms of delirium (determined by review of the subject's medical status with the treating (clinical) physician; standard blood chemistry lab work will be obtained if not checked within the preceding 30 days)
* History of sensitivity to sertraline
* Pregnant or breastfeeding

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No